AS1411: Additional Phase II data

Data from 59 evaluable patients in the open-label, U.S. Phase II showed that 10 and 40 mg/kg/day IV AS1411 plus cytarabine resulted in response rates of 21% (4/19) and 19% (4/21), respectively, vs. 5%...